869:
Efficacy of the SQ HDM SLIT-tablet on House Dust Mite Induced Allergic Conjunctivitis
Monday, March 5, 2018
South Hall A2 (Convention Center)
Hendrik Nolte, MD PhD, Harold S. Nelson, MD FAAAAI, Pascal M. Demoly, MD PhD, Ida M Smith, PhD, David I. Bernstein, MD FAAAAI
RATIONALE: Co-existence of allergic conjunctivitis is well recognized in patients with allergic rhinitis although the co-reporting frequency may be as low as 40%. Under-recognition and treatment of house dust mite (HDM)-induced allergic conjunctivitis may be due to the under-appreciation of eye symptoms in patients with HDM-induced allergic rhinitis. We present clinical data from 2 North American trials with the SQ HDM sublingual immunotherapy (SLIT)-tablet evaluating treatment effect on ocular symptoms.

METHODS: Trial 1 included 124 adult subjects with HDM-induced allergic rhinitis/rhinoconjunctivitis (AR/C) randomized to SQ HDM SLIT-tablet (6 or 12 SQ-HDM) or placebo for 24 weeks. Efficacy was assessed during HDM exposure in an environmental exposure chamber. Trial 2 included 1,482 adult/adolescent subjects with HDM-induced AR/C randomized to SQ HDM SLIT-tablet (12 SQ-HDM) or placebo for up to 12 months. A conjunctivitis symptom score (range 0-6) was constructed based on subjects’ rating of 2 ocular symptoms (watery eyes and itchy eyes).

RESULTS: In trial 1, 40% reported perennial allergic conjunctivitis. The average conjunctivitis symptom score during the HDM exposure session after 24 weeks of treatment showed a relative difference between both active treatment groups and placebo of -41% for 6 SQ-HDM and -68% for 12 SQ-HDM. In trial 2, 65% reported perennial allergic conjunctivitis. The average conjunctivitis daily symptom score obtained during the last 8 weeks of treatment showed a difference between treatment groups of -33.3% (95% CI, -47.1%, -18.5%).

CONCLUSIONS: The SQ HDM SLIT-tablet had a significant treatment effect on ocular symptoms in patients with HDM-induced AR/C.